<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="Review of Non-small cell lung cancer R3æ—å”éœ†
Epidemiology and Risk Factors  22è¬äºº/å¹´ cases w/ 16è¬ US deaths, #1 cause of cancer mortality 70% stage III/IV Cigarette smoking:  85% of all cases â†‘ w/ intensity & duration of smoking,   previous RT, å¤šç’°èŠ³é¦™çƒ´, æ°¡(åœ°ä¸‹å®¤), metals, synergy w/ smoking + asbestos  Pathology Adenocarcinomas of the lung (ADCL): 60% of all lung cancer, æœ€å¸¸è¦‹ â†‘ incidence, a/w è‚¥å¤§æ€§é—œç¯€ç—…è®Š hypertrophic osteoarthropathy, IHC: +TTF1 & +Napsin A, âˆ’p40"><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-mlkgi530p-htlin222.vercel.app/api/blog?templateTitle="><title>èœ¥èœ´èŠ±åœ’ğŸ¦ğŸŒ±ğŸª´ğŸŒ²</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.acd6336f837a791cf1889bb120dfb142.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.9422ebf6ba0889a950feb47330bafa38.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.16b530bdccc9be961108232e688f71ae.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'â€™':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=æœå°‹ placeholder="è«‹è¼¸å…¥åƒæ˜¯ï¼šhypertension ä¹‹é¡çš„ä¾†çœ‹æ²’æœ‰æ²’ä»€éº¼æœ‰è¶£çš„ğŸ³"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>èœ¥èœ´èŠ±åœ’ğŸ¦ğŸŒ±ğŸª´ğŸŒ²</a></h1><div class=spacer></div><div id=search-icon><p>æœå°‹</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">æœå°‹åœ–ç¤º</title><desc id="desc">æ‰“é–‹æœå°‹åœ–æ¨™</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>æ˜äº®æ¨¡å¼</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>é»‘æš—æ¨¡å¼</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><p class=meta>æœ€å¾Œæ›´æ–°æ–¼
Aug 28, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/slides/NSCLC.md rel=noopener>ğŸªš ç·¨è¼¯åŸå§‹æ–‡ä»¶</a></p><ul class=tags></ul><aside class=mainTOC><details><summary>ğŸ“’ç›®éŒ„</summary><nav id=TableOfContents><ol><li><a href=#epidemiology-and-risk-factors>Epidemiology and Risk Factors</a></li><li><a href=#pathology>Pathology</a><ol><li><a href=#adenocarcinomas-of-the-lung-adcl>Adenocarcinomas of the lung (ADCL):</a></li><li><a href=#squamous-cell-lung-cancers-sqclc>Squamous cell lung cancers (SQCLC):</a></li><li><a href=#others>Others:</a></li></ol></li><li><a href=#molecular-biology>Molecular Biology</a><ol><li><a href=#kras-mt>KRAS Mt:</a></li><li><a href=#egfr-mt>EGFR Mt:</a></li><li><a href=#alk-rearrangements>ALK Rearrangements:</a></li><li><a href=#ros-1-rearrangements>ROS 1 Rearrangements:</a></li><li><a href=#other-actionable-aberrations>Other actionable aberrations:</a></li><li><a href=#sqclcs>SQCLCs:</a></li></ol></li><li><a href=#screening-and-prevention>Screening and Prevention</a></li><li><a href=#clinical-manifestations>Clinical Manifestations</a></li><li><a href=#diagnostic-and-staging-evaluation>Diagnostic and Staging Evaluation</a><ol><li><a href=#imaging>Imaging:</a></li><li><a href=#mediastinal-evaluation>Mediastinal evaluation:</a></li><li><a href=#molecular-testing>Molecular Testing:</a></li></ol></li><li><a href=#staging>Staging</a></li><li><a href=#management>Management:</a><ol><li><a href=#pathologic-stage-i-to-iiia-n1>Pathologic Stage I to IIIA (N1)</a></li></ol></li><li><a href=#management-1>Management:</a><ol><li><a href=#pathologic-stage-iiia-n2-to-iiib-disease>Pathologic Stage IIIA (N2) to IIIB Disease</a></li></ol></li><li><a href=#management-2>Management:</a><ol><li><a href=#stage-iv-metastatic-disease>Stage IV Metastatic Disease</a></li><li><a href=#median-os>Median OS:</a></li><li><a href=#initial-tx>Initial Tx:</a></li><li><a href=#adenocarcinomas>Adenocarcinomas:</a></li><li><a href=#maintenance-tx>Maintenance Tx:</a></li><li><a href=#subsequent-therapies>Subsequent Therapies:</a></li></ol></li><li><a href=#targeted-therapy>Targeted Therapy</a><ol><li><a href=#egfr-mutant-tki>EGFR-mutant: TKI.</a></li><li><a href=#alk-rearranged>ALK-rearranged:</a></li></ol></li></ol></nav></details></aside><a href=#review-of-non-small-cell-lung-cancer><h1 id=review-of-non-small-cell-lung-cancer><span class=hanchor arialabel=Anchor># </span>Review of Non-small cell lung cancer</h1></a><p>R3æ—å”éœ†</p><a href=#epidemiology-and-risk-factors><h2 id=epidemiology-and-risk-factors><span class=hanchor arialabel=Anchor># </span>Epidemiology and Risk Factors</h2></a><ul><li>22è¬äºº/å¹´ cases w/ 16è¬ US deaths,</li><li>#1 cause of cancer mortality</li><li>70% stage III/IV</li><li>Cigarette smoking:<ul><li>85% of all cases</li><li>â†‘ w/ intensity & duration of smoking,</li></ul></li><li>previous RT,</li><li>å¤šç’°èŠ³é¦™çƒ´, æ°¡(åœ°ä¸‹å®¤), metals, synergy w/ smoking + asbestos</li></ul><a href=#pathology><h2 id=pathology><span class=hanchor arialabel=Anchor># </span>Pathology</h2></a><a href=#adenocarcinomas-of-the-lung-adcl><h3 id=adenocarcinomas-of-the-lung-adcl><span class=hanchor arialabel=Anchor># </span>Adenocarcinomas of the lung (ADCL):</h3></a><p>60% of all lung cancer, æœ€å¸¸è¦‹
â†‘ incidence, a/w è‚¥å¤§æ€§é—œç¯€ç—…è®Š hypertrophic osteoarthropathy,
IHC: <code>+TTF1</code> & <code>+Napsin A</code>, <code>âˆ’p40</code></p><a href=#squamous-cell-lung-cancers-sqclc><h3 id=squamous-cell-lung-cancers-sqclc><span class=hanchor arialabel=Anchor># </span>Squamous cell lung cancers (SQCLC):</h3></a><p>20% of all lung strongly a/w smoking,
a/w hypercalcemia 2Â° to PTHrP release,
IHC: <code>â€“TTF1</code>, <code>+p40</code>, <code>+p63</code></p><hr><a href=#others><h3 id=others><span class=hanchor arialabel=Anchor># </span>Others:</h3></a><ul><li>Adenosquamous (&lt;4%),</li><li>Sarcomatoid (&lt;1%),</li><li>Large Cell Neuroendocrine Carcinoma (&lt;6%),</li><li>Carcinoids (&lt;5%)<ul><li>uncommon neuroendocrine epithelial malignancies</li></ul></li></ul><a href=#molecular-biology><h2 id=molecular-biology><span class=hanchor arialabel=Anchor># </span>Molecular Biology</h2></a><a href=#kras-mt><h3 id=kras-mt><span class=hanchor arialabel=Anchor># </span>KRAS Mt:</h3></a><ul><li>25% of <code>ADCL</code>,</li><li>a/w smoking (transversions: G12C, G12V) but present in 6% of never-smokers (transitions: G12D).</li><li>Confers EGFR TKI resistance (CCR 2008;14:5731) -> ä¸è‰¯é å¾Œ</li><li>No overlap w/ EGFR Mts, ALK/ROS1 rearrangements.</li></ul><hr><a href=#egfr-mt><h3 id=egfr-mt><span class=hanchor arialabel=Anchor># </span>EGFR Mt:</h3></a><p>21% all pts, 43% never-smokers w/ ADCL,</p><ul><li>exon 19 deletions LREA (45%)</li><li>exon 21 L858R (40%),</li><li>exon 18 (G719X) : äºŒä»£</li><li>exon 21 (L861Q), confer EGFR TKI Sn,<ul><li>initially described in female Asian never-smokers but also present in smokers. ğŸ‘©â€ğŸ¦±</li></ul></li><li>Exon 20 insertions: é å¾Œä¸è‰¯ğŸ˜¥</li><li>Acquired T790M Mt confers EGFR TKI resistance after 8â€“16 mos</li></ul><hr><a href=#alk-rearrangements><h3 id=alk-rearrangements><span class=hanchor arialabel=Anchor># </span>ALK Rearrangements:</h3></a><ul><li>2â€“7%</li><li>a/w younger males ğŸ‘¦</li><li>never/light smokingğŸš¬ hx,</li><li>w/ signet-ring ADCL histology, resistant to EGFR TKI,</li><li>confers Sn to <code>crizotinib</code> (NEJM 2010;363:1693).</li><li>Not usually found in SCC but can be in mixed histology.</li></ul><hr><a href=#ros-1-rearrangements><h3 id=ros-1-rearrangements><span class=hanchor arialabel=Anchor># </span>ROS 1 Rearrangements:</h3></a><ul><li>1â€“2% of ADCL, younger women ğŸ‘±â€â™€ï¸, never smokersğŸš­.</li><li>Usually negative for EGFR, KRAS, & ALK rearrangements (JCO 2012;30:863)</li></ul><a href=#other-actionable-aberrations><h3 id=other-actionable-aberrations><span class=hanchor arialabel=Anchor># </span>Other actionable aberrations:</h3></a><ul><li>BRAF 2% : Dabrafenib + trametinib (Lancet Onc 2016;17:984),</li><li>RET Fusions 1% : Selpercatinib,</li><li>HER2 Amp/Mt 3%, PIK3CA &lt;1%,</li><li>MET Amp &lt;1%, MET exon 14 Mts 3â€“4%</li></ul><hr><a href=#sqclcs><h3 id=sqclcs><span class=hanchor arialabel=Anchor># </span>SQCLCs:</h3></a><ul><li>FGFR1(Fibroblast growth factor receptor 1) Amp 20%,</li><li>DDR2 Mt 4%, potential Sn to dasatinib (CML)</li><li>SOX2 Amp 8%</li><li>PIK3CA Mt 4%</li><li>PTEN Mt 10%</li><li>AKT Mt 6%</li></ul><blockquote><p>(Nature 2012;489:519; JCO 2012;30:abstr 7505)</p></blockquote><a href=#screening-and-prevention><h2 id=screening-and-prevention><span class=hanchor arialabel=Anchor># </span>Screening and Prevention</h2></a><ul><li>æ¯å¹´ low-dose CT: 20% mortality benefit in National Lung Screening Trial, NNT = 320 (ç¯©320å€‹äººæ•‘ä¸€å€‹äºº)<ul><li>Ages 55â€“74 (up to 80 if good health),</li><li>â‰¥30 pack y, quit &lt;15 y ago</li></ul></li><li>Smoking cessation: Most effective method of prevention (including 2nd lung primary)</li></ul><a href=#clinical-manifestations><h2 id=clinical-manifestations><span class=hanchor arialabel=Anchor># </span>Clinical Manifestations</h2></a><ul><li>10% ç„¡ç—‡ç‹€ã€æ„å¤–ç™¼ç¾by imaging ğŸ“¸</li><li>Cough, hemoptysis, dyspnea, postobstructive pneumonia</li><li>Regional spread: pleural effusion, Pancoast syndrome (apical tumors), SVC syndrome</li><li>Extrathoracic metastases: ğŸ§ brain, ğŸ¦´bone, liver, adrenal</li><li><strong>Paraneoplastic syndromes: (1)SIADH, (2)hypercalcemia, (2)hypertrophic pulmonary osteoarthropathy</strong></li></ul><a href=#diagnostic-and-staging-evaluation><h2 id=diagnostic-and-staging-evaluation><span class=hanchor arialabel=Anchor># </span>Diagnostic and Staging Evaluation</h2></a><a href=#imaging><h3 id=imaging><span class=hanchor arialabel=Anchor># </span>Imaging:</h3></a><ul><li>CT chest down to <code>adrenals</code>, PET scan to evaluate for distant metastasis, MR brain for pts treated w/ curative intent or symptoms,</li><li>PFTs preoperatively</li><li>Tissue:<ul><li>bronchoscopy,</li><li>CT-guided needle bx, thoracentesis, or VATS.</li></ul></li></ul><hr><ul><li>check PD-L1</li><li>comprehensive molecular testing; <code>NGS preferred</code>.</li><li><strong>Proceeding to surgery w/o bx</strong> is appropriate for Stage I.</li></ul><hr><a href=#mediastinal-evaluation><h3 id=mediastinal-evaluation><span class=hanchor arialabel=Anchor># </span>Mediastinal evaluation:</h3></a><p>Considered for nodes >1 cm on CT or PET+ via EBUS-guided bronchoscopy or mediastinoscopy</p><a href=#molecular-testing><h3 id=molecular-testing><span class=hanchor arialabel=Anchor># </span>Molecular Testing:</h3></a><ul><li>KRAS</li><li>EGFR</li><li>ALK</li><li>ROS1</li><li>BRAF</li><li>MET, RET, BRAF, HER2</li></ul><a href=#staging><h2 id=staging><span class=hanchor arialabel=Anchor># </span>Staging</h2></a><ul><li>Stage I : T1-2N0.</li><li>Stage IIA : T2N0</li><li>Stage IIB : T1-2N1, T3N0.</li><li>Stage IIIA: <code>T1-2N2</code>, <code>T3N1</code>, <code>T4N0-1</code>.</li><li>Stage IIIB: T1-2N3, T3-4N2.</li><li>Stage IIIC: T3-4N3.</li><li>Stage IV: Contralateral lung nodule (M1a), pleural or pericardial metastasis/effusion (M1a), single extrathoracic met (M1b), multiple extrathoracic mets (M1c)</li></ul><a href=#management><h2 id=management><span class=hanchor arialabel=Anchor># </span>Management:</h2></a><a href=#pathologic-stage-i-to-iiia-n1><h3 id=pathologic-stage-i-to-iiia-n1><span class=hanchor arialabel=Anchor># </span>Pathologic Stage I to IIIA (N1)</h3></a><a href=#surgery><h4 id=surgery><span class=hanchor arialabel=Anchor># </span>Surgery:</h4></a><p>Lobectomy w/ mediastinal node dissection preferred.
If + margins, re-resection preferred over RT.</p><a href=#rt><h4 id=rt><span class=hanchor arialabel=Anchor># </span>RT:</h4></a><p>If medically inoperable:</p><ul><li>SBRT(èº«é«”ç«‹é«”å®šä½æ”¾å°„æ²»ç™‚), standard RT (60 Gy = 6000 cGy)
radiofrequency or cryoablation.</li></ul><blockquote><p>test</p></blockquote><hr><a href=#adjuvant-chemo><h4 id=adjuvant-chemo><span class=hanchor arialabel=Anchor># </span>Adjuvant Chemo:</h4></a><ul><li>Not recommended for Stage IA;</li><li>consider for Stage IB (med onc consult mandatory). â†‘ OS for Stage IIâ€“IIIA, <code>CISplatin doublet</code> for 4 cycles (LACE JCO 2008;26:3552),</li><li>most studies used <code>CIS/vinorelbine</code> (NEJM 2005;352:2589);</li><li><code>CIS/pemetrexed</code> & <code>CIS/docetaxel</code> w/ similar efficacy & â†‘ tolerability.</li></ul><hr><a href=#adjuvant-targeted-therapy><h4 id=adjuvant-targeted-therapy><span class=hanchor arialabel=Anchor># </span>Adjuvant Targeted Therapy:</h4></a><ul><li>EGFR TKIs have DFS benefit, OS benefit inconclusive</li></ul><a href=#port-op-rt><h4 id=port-op-rt><span class=hanchor arialabel=Anchor># </span>port-op RT:</h4></a><ul><li>N2 nodes, +margins. Radiation Oncology consultation <code>mandatory</code> for N2.</li></ul><a href=#multiple-lung-cancers><h4 id=multiple-lung-cancers><span class=hanchor arialabel=Anchor># </span>Multiple Lung Cancers:</h4></a><ul><li>Need to bx all lesions.</li></ul><a href=#management-1><h2 id=management-1><span class=hanchor arialabel=Anchor># </span>Management:</h2></a><a href=#pathologic-stage-iiia-n2-to-iiib-disease><h3 id=pathologic-stage-iiia-n2-to-iiib-disease><span class=hanchor arialabel=Anchor># </span>Pathologic Stage IIIA (N2) to IIIB Disease</h3></a><p>Sequence of surgery, RT & chemo varies.</p><a href=#induction><h4 id=induction><span class=hanchor arialabel=Anchor># </span>Induction:</h4></a><p>If resectable, <code>neoadjuvant</code> chemo to best response followed by resection + PORT. Neoadjuvant chemoRT does not improve outcomes.</p><hr><a href=#concurrent-chemoradiation><h4 id=concurrent-chemoradiation><span class=hanchor arialabel=Anchor># </span>Concurrent Chemoradiation:</h4></a><p>If unresectable (multiple +N2 LN>3 cm), definitive concurrent chemoradiation (JCO 1999;17:2692),</p><a href=#regimens><h5 id=regimens><span class=hanchor arialabel=Anchor># </span>regimens:</h5></a><p>CIS/pemetrexed, CIS/vinblastine, CIS/etoposide, carboplatin/paclitaxel.</p><a href=#pancoast-tumor><h4 id=pancoast-tumor><span class=hanchor arialabel=Anchor># </span>Pancoast tumor:</h4></a><p>ChemoRT (<code>CIS/etoposide</code> + 45 Gy) followed by surgery (T3N0-1) improves resectability (SWOG 9416 JCO 2007;25:313). If unresectable (T4N0-1), chemoRT.</p><a href=#management-2><h2 id=management-2><span class=hanchor arialabel=Anchor># </span>Management:</h2></a><a href=#stage-iv-metastatic-disease><h3 id=stage-iv-metastatic-disease><span class=hanchor arialabel=Anchor># </span>Stage IV Metastatic Disease</h3></a><a href=#median-os><h3 id=median-os><span class=hanchor arialabel=Anchor># </span>Median OS:</h3></a><ul><li>6-mo BSC (best supportive care)</li><li>10-mo <code>plat doublet</code>,</li><li>12-mo <code>plat doublet</code> + <code>bevacizumab or necitumumab</code> (NEJM 2006;355:2542; Lancet Onc 2015;16:763)</li></ul><hr><a href=#initial-tx><h3 id=initial-tx><span class=hanchor arialabel=Anchor># </span>Initial Tx:</h3></a><p>-<code>Pembrolizumab</code> if PD-L1>50% (response rate~45%) (NEJM 2016;375:1823).</p><ul><li>If PD-La &lt;50%, 4â€“6 cycles of platinum doublet (response rate~30%).</li></ul><a href=#adenocarcinomas><h3 id=adenocarcinomas><span class=hanchor arialabel=Anchor># </span>Adenocarcinomas:</h3></a><ul><li><code>CIS/peme</code> Â± <code>bevacizumab</code> (if eligible: no-SQCLC, no hemoptysis)</li></ul><hr><a href=#sqclc><h4 id=sqclc><span class=hanchor arialabel=Anchor># </span>SQCLC:</h4></a><ul><li><code>CIS/gem</code> Â± <code>necitumumab</code> (SQUIRE Lancet Onc 2015;16:763)</li><li><code>Carboplatin/paclitaxel</code> (any histology)</li></ul><hr><a href=#maintenance-tx><h3 id=maintenance-tx><span class=hanchor arialabel=Anchor># </span>Maintenance Tx:</h3></a><ul><li>For complete remission, partial remission, strable disease after 4â€“6 cycles of platinum doublet.</li><li>Discontinue platinum.</li><li>Continue <code>peme</code> â†‘ OS (PARAMOUNT JCO 2013;31:2895),</li><li><code>peme</code> + <code>Bev</code> â†‘ PFS (AVAPERL JCO 2013;31:3004),</li><li><code>GEM</code> â†‘ PFS (JCO 2012;30:3516)</li></ul><hr><a href=#subsequent-therapies><h3 id=subsequent-therapies><span class=hanchor arialabel=Anchor># </span>Subsequent Therapies:</h3></a><p>Checkpoint inhibitors encouraged:</p><ul><li><code>nivolumab</code> (NEJM 2015;373:1627),</li><li><code>pembrolizumab</code> (Lancet 2016;387:1540),</li><li><code>atezolizumab</code> (Lancet 2016;387:1837),</li><li><code>ramucirumab</code> + <code>docetaxel</code> (Lancet 2014;384:665),</li></ul><hr><a href=#limited-metastatic-sites-oligo-metastases><h4 id=limited-metastatic-sites-oligo-metastases><span class=hanchor arialabel=Anchor># </span>Limited Metastatic Sites: (oligo-metastases):</h4></a><p>Consider surgery or radiation</p><a href=#rt-to-symptomatic-sites><h4 id=rt-to-symptomatic-sites><span class=hanchor arialabel=Anchor># </span>RT to Symptomatic Sites:</h4></a><p>lung, brain (WBRT or SRS), bone lesions, SVC syndrome</p><a href=#bone-metastases><h4 id=bone-metastases><span class=hanchor arialabel=Anchor># </span>Bone Metastases:</h4></a><p><code>Denosumab</code> or <code>zoledronic acid</code> reduces skeletal events</p><a href=#targeted-therapy><h2 id=targeted-therapy><span class=hanchor arialabel=Anchor># </span>Targeted Therapy</h2></a><a href=#egfr-mutant-tki><h3 id=egfr-mutant-tki><span class=hanchor arialabel=Anchor># </span>EGFR-mutant: TKI.</h3></a><ul><li>ç¬¬ä¸€ä»£<code>erlotinib</code>, <code>gefitinib</code>,</li><li>ç¬¬äºŒä»£<code>afatinib</code>,</li></ul><p>â†‘ PFS, improved RR/PFS compared to <code>plat doublet</code> in 1st-line, but not OS (IPASS NEJM 2010;362:2380).</p><a href=#å‰¯ä½œç”¨><h4 id=å‰¯ä½œç”¨><span class=hanchor arialabel=Anchor># </span>å‰¯ä½œç”¨:</h4></a><ul><li>Rash (30â€“50% pts, Tx: Moisturizers, abx, topical steroids)</li><li>diarrhea</li></ul><hr><a href=#subsequent-tx><h4 id=subsequent-tx><span class=hanchor arialabel=Anchor># </span>Subsequent Tx:</h4></a><ul><li><code>osimertinib</code> if T790M+ (50% resistance cases) (NEJM 2015;372:1689) or progressive CNS dz,</li><li>chemotherapy if T790M- or continuation of TKI (erlotinib, gefitinib, afatinib) Â± local therapy for progression (JCO 2013;31:3335).</li></ul><hr><a href=#alk-rearranged><h3 id=alk-rearranged><span class=hanchor arialabel=Anchor># </span>ALK-rearranged:</h3></a><a href=#subsequent-tx-1><h4 id=subsequent-tx-1><span class=hanchor arialabel=Anchor># </span>Subsequent Tx:</h4></a><ul><li>rebiopsy & choose agent <code>ceRitinib or criZotinib</code> based on sensitivity of resistance Mt (Cancer Discov 2016;6:1118).</li><li><code>Pemetrexed</code> is preferred chemotherapy.</li></ul><hr><a href=#ros1-rearranged><h4 id=ros1-rearranged><span class=hanchor arialabel=Anchor># </span>ROS1-rearranged:</h4></a><ul><li><code>Crizotinib</code> (RR~72%) (NEJM 2014;371:1963).</li><li>Toxicity: Fluid retention, visual changes.</li><li>Resistant dz is not sensitive to alectinib or ceritinib.</li></ul><a href=#met-amplification-or-exon-14-skipping-mt><h4 id=met-amplification-or-exon-14-skipping-mt><span class=hanchor arialabel=Anchor># </span>MET (amplification or Exon 14 skipping Mt):</h4></a><ul><li>criZotinib</li></ul><hr><a href=#ret-rearranged><h4 id=ret-rearranged><span class=hanchor arialabel=Anchor># </span>RET-rearranged:</h4></a><ul><li>caboZantinib, venDatinib</li></ul><a href=#braf-v600e><h4 id=braf-v600e><span class=hanchor arialabel=Anchor># </span>BRAF (V600E):</h4></a><ul><li>daBrafenib + traMetinib or vemuRafenib + cobiMetinib</li></ul><a href=#her2erbb2><h4 id=her2erbb2><span class=hanchor arialabel=Anchor># </span>HER2/ERBB2:</h4></a><ul><li>Trastuzumab, aFatinib</li></ul><a href=#kras><h4 id=kras><span class=hanchor arialabel=Anchor># </span>KRAS:</h4></a><ul><li>No targeted therapy available. May indicate higher RR w/ anti-PD-L1.</li></ul></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>â†©ï¸ åå‘é€£çµ</h3><ul class=backlinks><li>ğŸ¤­æ²’æœ‰æ‰¾åˆ°åå‘é€£çµ</li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>ğŸ¤¯äº’å‹•åœ–</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>æœ¬ç¶²ç«™æ˜¯ç”± Hsieh-Ting Lin ä»¥â¤ï¸ ç”¨ <a href=https://github.com/jackyzha0/quartz>Quartz</a>é€™å€‹é…·æ±è¥¿ç¨®å‡ºä¾†ğŸª´ , Â© 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>ğŸ é¦–é </a></li><li><a href=https://www.facebook.com/htlin.lizard>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://htlin222.medium.com>Medium</a></li></ul></footer></div></div></body></html>